Pharmaceutical Executive
August 26, 2015
Features
35
8
A patient has been prescribed a drug, your company’s drug. What next? Is there an app for that?Step back and think about the patient journey to this point. In the course of the joys and trials of day-to-day living, a patient may be afflicted with early symptoms. Be they minor or severe, a patient hopefully receives a diagnosis, often after missed opportunities and wrong turns than can stretch for years.
August 14, 2015
Features
35
8
The need for biopharma executives to combine a "culture of quality" with value-added processes and improvements in the area drug manufacturing is critical. Here are steps and strategies than can help.
August 14, 2015
Columns
35
8
Commercial success for pharma brands now demands proactive strategies and interventions
August 13, 2015
From the Editor
35
8
BIG DATA IS BIG-it’s the one trend in healthcare that demands to be described in superlatives.
August 12, 2015
Columns
35
8
Alzheimer’s disease (AD) researchers have seen more than their share of hopefulness and disillusionment over the years. Recent apparent gains targeting one of the disease’s two molecular bull’s-eyes may have reinvigorated drug development, or it may have set developers and investors up for letdown once more. To follow the news coming out of July’s Alzheimer’s Association International Conference in Washington, one had to be prepared for both glass half-full and half-empty interpretations.
August 11, 2015
Features
35
8
Experts from industry and academia probe the changing role of the pharmacoepidemiology function as it grapples with the challenges of big data analytics, tightening drug safety requirements, growing post-approval study burdens, and payer expectations around the application of real-world evidence.
August 05, 2015
Columns
35
8
The case of Amgen v. Sandoz signals that preliminary injunctions will play major role in future patent disputes
August 05, 2015
Columns
35
8
FDA reform may get tangled up in user fee negotiations, budget debate
August 01, 2015
Columns
35
8
The volatility of nation's crisis could pose greater challenges down the line
August 01, 2015
Special Sponsored Section
35
8
Despite rising healthcare costs, Algeria, the second-largest pharmaceutical market in Africa, remains optimistic about its pharma sector, which is riding the momentum of recent healthcare reforms. Manufacturing challenges and a growing prevalence of chronic disease, however, offer pause to the bright scenario.